<DOC>
	<DOC>NCT00805909</DOC>
	<brief_summary>The purpose of the study is to determine the safety and tolerability of NI-0401 and whether NI-0401 can reverse BpACR.</brief_summary>
	<brief_title>NI-0401 in Patients With Acute Renal Allograft Rejection</brief_title>
	<detailed_description />
	<criteria>Main inclusion Criteria: evidence of cellular rejection in a renal biopsy according to Bannff 97 criteria rise in Serum Creatinine concentration by &gt;20% compared to baseline value Main previous therapy with antiCD3 mAB(OKT3) or antilymphocytes polyclonal antibodies (ATG, Atgam) patients with cardiac insufficiency or fluid overload severe HLA sensitization (&gt;50% panel reactive antibodies prior transplantation) defined concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>